{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T22:52:50Z","timestamp":1779403970596,"version":"3.53.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.medcli.2018.02.016","type":"journal-article","created":{"date-parts":[[2018,4,24]],"date-time":"2018-04-24T13:56:29Z","timestamp":1524578189000},"page":"329-335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["S\u00edndrome hemol\u00edtico ur\u00e9mico: estado actual"],"prefix":"10.1016","volume":"151","author":[{"given":"Teresa","family":"Cavero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2018.02.016_bib0300","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2018.02.016_bib0305","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u00abKidney Disease: Improving Global Outcomes\u00bb (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.medcli.2018.02.016_bib0310","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1681\/ASN.V961126","article-title":"The pathogenesis and treatment of hemolytic uremic syndrome","volume":"9","author":"Kaplan","year":"1998","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0315","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1681\/ASN.2004100861","article-title":"Hemolytic uremic syndrome","volume":"16","author":"Noris","year":"2005","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0320","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1128\/IAI.64.8.3294-3300.1996","article-title":"Translocation of Shiga toxin across polarized intestinal cells in tissue culture","volume":"64","author":"Acheson","year":"1996","journal-title":"Infect Immun."},{"key":"10.1016\/j.medcli.2018.02.016_bib0325","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ki.1997.170","article-title":"Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells","volume":"51","author":"Van Setten","year":"1997","journal-title":"Kidney Int."},{"key":"10.1016\/j.medcli.2018.02.016_bib0330","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0882-4010(03)00100-1","article-title":"Shiga toxin induces decreased expression of the anti-apoptotic protein Mcl-1 concomitant with the onset of endothelial apoptosis","volume":"35","author":"Erwert","year":"2003","journal-title":"Microb Pathog."},{"key":"10.1016\/j.medcli.2018.02.016_bib0335","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0034-1375296","article-title":"Genetics of atypical hemolytic uremic syndrome (aHUS)","volume":"40","author":"Rodr\u00edguez de C\u00f3rdoba","year":"2014","journal-title":"Semin Thromb Hemost."},{"key":"10.1016\/j.medcli.2018.02.016_bib0340","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0345","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2018.02.016_bib0350","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/S0140-6736(03)14742-3","article-title":"Familial haemolytic uraemic syndrome and an MCP mutation","volume":"362","author":"Noris","year":"2003","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2018.02.016_bib0355","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1073\/pnas.0603420103","article-title":"Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome","volume":"104","author":"Goicoechea de Jorge","year":"2007","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.medcli.2018.02.016_bib0360","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","article-title":"Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome","volume":"112","author":"Fr\u00e9meaux-Bacchi","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2018.02.016_bib0365","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1681\/ASN.2004050380","article-title":"Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome","volume":"16","author":"Dragon-Durey","year":"2005","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0370","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.medcli.2018.02.016_bib0375","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: A study from the SFGM-TC","volume":"99","author":"De Fontbrune","year":"2015","journal-title":"Transplantation."},{"key":"10.1016\/j.medcli.2018.02.016_bib0380","first-page":"704371","article-title":"36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature","volume":"2014","author":"Strakhan","year":"2014","journal-title":"Case Rep Hematol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0385","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ckj\/sfv101","article-title":"Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome","volume":"8","author":"Thomas","year":"2015","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.medcli.2018.02.016_bib0390","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.kint.2017.06.022","article-title":"A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome","volume":"93","author":"Huerta","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.medcli.2018.02.016_bib0395","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2215\/CJN.00280117","article-title":"Hemolytic uremic syndrome in pregnancy and postpartum","volume":"12","author":"Bruel","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0400","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0405","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/bjh.12686","article-title":"Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy","volume":"64","author":"Starck","year":"2014","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0410","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5414\/CN108163","article-title":"Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: A case report","volume":"83","author":"Safa","year":"2015","journal-title":"Clin Nephrol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0415","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ckj\/sft078","article-title":"Eculizumab and drug-induced haemolytic-uraemic syndrome","volume":"6","author":"Faguer","year":"2013","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.medcli.2018.02.016_bib0420","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases","volume":"91","author":"Lechner","year":"2012","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.medcli.2018.02.016_bib0425","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.2217\/fon.14.113","article-title":"Metastatic cancer-related thrombotic microangiopathies: a cohort study","volume":"10","author":"Ducos","year":"2014","journal-title":"Future Oncol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0430","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1542\/peds.2012-2581","article-title":"Combined pulmonary hypertension and renal thrombotic microangiopathy in cobalamin C deficiency","volume":"132","author":"K\u00f6mhoff","year":"2013","journal-title":"Pediatrics."},{"key":"10.1016\/j.medcli.2018.02.016_bib0435","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.medcli.2018.02.016_bib0440","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1007\/s00467-010-1606-y","article-title":"Neurological involvement in a child with atypical hemolytic uremic syndrome","volume":"25","author":"Koehl","year":"2010","journal-title":"Pediatr Nephrol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0445","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0450","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00467-012-2131-y","article-title":"Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics","volume":"27","author":"Geerdink","year":"2012","journal-title":"Pediatr Nephrol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0455","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-2006-939767","article-title":"Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome","volume":"32","author":"Zimmerhackl","year":"2006","journal-title":"Semin Thromb Hemost."},{"key":"10.1016\/j.medcli.2018.02.016_bib0460","first-page":"5","article-title":"Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities","volume":"91","author":"Timmermans SAMEG","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.medcli.2018.02.016_bib0465","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40620-016-0357-7","article-title":"Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab","volume":"30","author":"Asif","year":"2017","journal-title":"J Nephrol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0470","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.2169\/internalmedicine.55.6332","article-title":"Malignant hypertension with thrombotic microangiopathy","volume":"55","author":"Mitaka","year":"2016","journal-title":"Intern Med."},{"key":"10.1016\/j.medcli.2018.02.016_bib0475","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/0009922811412942","article-title":"Atypical haemolytic-uremic syndrome in a child presenting with malignant hypertension","volume":"52","author":"Totina","year":"2013","journal-title":"Clin Pediatr (Phila)."},{"key":"10.1016\/j.medcli.2018.02.016_bib0480","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00467-002-0973-4","article-title":"Peripheral gangrene complicating hemolytic uremic syndrome in a child","volume":"18","author":"Ozel","year":"2003","journal-title":"Pediatr Nephrol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0485","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1542\/peds.2012-0903","article-title":"Peripheral gangrene in children with atypical hemolytic uremic syndrome","volume":"131","author":"Malina","year":"2013","journal-title":"Pediatrics."},{"key":"10.1016\/j.medcli.2018.02.016_bib0490","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.3174\/ajnr.A0965","article-title":"Proximal cerebral artery stenosis in a patient with hemolytic uremic syndrome","volume":"29","author":"Vergouwen","year":"2008","journal-title":"Am J Neuroradiol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0495","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ndt\/gfq319","article-title":"Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation","volume":"25","author":"Loirat","year":"2010","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.medcli.2018.02.016_bib0500","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/ndt\/gfq160","article-title":"Myocardial infarction is a complication of factor H-associated atypical HUS","volume":"25","author":"Sall\u00e9e","year":"2010","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.medcli.2018.02.016_bib0505","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s00467-007-0540-0","article-title":"Ocular involvement in hemolytic uremic syndrome due to factor H deficiency \u2014 are there therapeutic consequences?","volume":"22","author":"Larakeb","year":"2007","journal-title":"Pediatr Nephrol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0510","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2018.02.016_bib0515","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.medcli.2018.02.016_bib0520","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2018.02.016_bib0525","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome","volume":"13","author":"Le Quintrec","year":"2013","journal-title":"Am J Transplant."},{"key":"10.1016\/j.medcli.2018.02.016_bib0530","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.ajkd.2008.07.038","article-title":"Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials","volume":"53","author":"Michael","year":"2009","journal-title":"Am J Kidney."},{"key":"10.1016\/j.medcli.2018.02.016_bib0535","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1160\/TH08-05-0322","article-title":"Autoantibodies in haemolytic uraemic syndrome (HUS)","volume":"101","author":"Skerka","year":"2009","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.medcli.2018.02.016_bib0540","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/ndt\/gfn063","article-title":"Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome","volume":"23","author":"Kwon","year":"2008","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.medcli.2018.02.016_bib0545","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s00467-007-0438-x","article-title":"Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate","volume":"22","author":"Cho","year":"2007","journal-title":"Pediatr Nephrol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0550","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1053\/j.ajkd.2004.10.018","article-title":"Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15","volume":"45","author":"Licht","year":"2005","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.medcli.2018.02.016_bib0555","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","article-title":"Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update","volume":"66","author":"Ardissino","year":"2015","journal-title":"Am J Kidney."},{"key":"10.1016\/j.medcli.2018.02.016_bib0560","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0565","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/ndt\/gft470","article-title":"Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab","volume":"29","author":"Delmas","year":"2014","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.medcli.2018.02.016_bib0570","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/ndt\/gfv255","article-title":"Hypertension and mild chronic kidney disease persist following severe haemolytic uraemic syndrome caused by Shiga toxin-producing Escherichia coli O104:H4 in adults","volume":"31","author":"Derad","year":"2016","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.medcli.2018.02.016_bib0575","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1053\/j.ajkd.2015.06.032","article-title":"Treatment of congenital thrombotic thrombocytopenic purpura with eculizumab","volume":"66","author":"Pecoraro","year":"2015","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.medcli.2018.02.016_bib0580","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneph.2012.195","article-title":"STEC-HUS, atypical HUS and TTP are all diseases of complement activation","volume":"8","author":"Noris","year":"2012","journal-title":"Nat Rev Nephrol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0585","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2215\/CJN.00050505","article-title":"Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background","volume":"1","author":"Bresin","year":"2006","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.medcli.2018.02.016_bib0590","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1399-3046.2008.00910.x","article-title":"Hemolytic uremic syndrome recurrence after renal transplantation","volume":"12","author":"Loirat","year":"2008","journal-title":"Pediatr Transplant."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775318301556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775318301556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T21:28:38Z","timestamp":1661030918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775318301556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0025775318301556"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2018.02.016","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"S\u00edndrome hemol\u00edtico ur\u00e9mico: estado actual","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2018.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}